Ranbaxy woes don't seem to end - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy woes don't seem to end

Sep 25, 2013

Here is today's recommended reading list from Equitymaster...

Ranbaxy woes don't seem to end
Since the first legal case slammed in 2007 by a former employee for forging drug clinical trial studies, the ghost of inadequate practices keep haunting Ranbaxy. Recently, United States Food & Drug Administration imposed a ban on the firm's new plant at Mohali in Punjab, making it the third ban on a Ranbaxy plant in five years. In its rush to capitalize on the growing overseas market of cheap generic drugs, the company seems to have gone lax on quality issues. Read on to know more... (The Economist Newspaper Limited)

Functioning of economy, demystified
Since the eruption of the global financial crisis in 2008, the functioning of economies across the world have been a heated topic of debate. In this video Mr Ray Dalio explains the working of the economy in layman's terms. Watch it to understand how the economy can impact the well being of its inhabitants. (Value Investing World)

Corporate India continues to reel under rate hike
The recent hike in the repo rate further compounded funding problems of corporate India. With companies already struggling with the economic slowdown and falling profits, the rising cost of funds is adding on to their burden. Companies are deferring bond issues or raising funds at higher market rates. Read on to find out how high rates are impacting the financial health of companies... (Thomson Reuters)

Simplifying energy needs of industry
In a bid to expedite investments in the energy sector and bring in more transparency, the government has approved auction-based bidding for coal mining licenses by private companies. While bidding will be competitive for deregulated sectors such cement and steel, discounts will be offered to the regulated power sector on the basis of tariff-based bidding. Read on to know more... (Thomson Reuters)

Are dividends value accretive?
The surplus cash generated by any business can either be ploughed back into the business or returned back to shareholders. In the latter case, the cash can be returned in the form of dividends or share buyback. Which among the two options will maximize shareholder's wealth? Read on to find out... (Inside Investing)

Madhu Gupta

Madhu Gupta (Research Analyst), ValuePro has a post graduate degree in both physics and finance. Having worked with India's leading economic research agency, she has a natural flair for numbers and analytics. She brings with her a near-decade long rich experience in the field of finance. A firm believer of the principles of value investing, she looks for robust businesses with durable competitive advantages.

This article is for information purposes only. The link in this article will let the User leave www.equitymaster.com and proceed to the linked article. The User's use of each such site is subject to Terms of Use on www.equitymaster.com and other terms of use, if any, contained within each such site. Any data and charts if used, in the article have not been authenticated by Equitymaster and Equitymaster do not claim it to be accurate nor accept any responsibility for the same. The views, if any in the linked article are not of Equitymaster. Equitymaster will not be responsible for any loss or liability incurred to any person as a consequence of his or any other person on his behalf taking any investment decisions based on this article. Please read the detailed Terms of Use of the web site.

Equitymaster requests your view! Post a comment on "Ranbaxy woes don't seem to end". Click here!


More Views on News

How Much Money Should an Investor Set Aside for Trading? (Fast Profits Daily)

Sep 21, 2020

In this video, I'll give you a simple equation which you can use to decide how much money you can set aside for trading.

Kotak Standard Multicap Fund: Strategizing Growth with Focused Approach (Outside View)

Sep 21, 2020

PersonalFN's analysis on the features and performance of Kotak Standard Multicap Fund.

Sensex Can Go to 25,000 Before it Goes to 60,000. Are You Prepared? (Profit Hunter)

Sep 21, 2020

Am I expecting a big crack in the Sensex and what next?

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

Sundaram Bluechip Fund: Will Hold the Stable Horses (Outside View)

Sep 18, 2020

PersonalFn briefly outlines the newly launched NFO note HSBC Corporate Bond Fund.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why am I Recommending Caution? (Fast Profits Daily)

Sep 9, 2020

This is why I have changed my short-term view on the market.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 21, 2020 (Close)